Freda K Stevenson

List of Publications by Year
in descending order

191	12,220	28274	27406
papers	citations	55 h-index	106 g-index

195	195	195	8974
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells. Exploration of Targeted Anti-tumor Therapy, 2022, 3, 37-49.	0.8	2
2	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. Cellular Signalling, 2022, 94, 110311.	3.6	5
3	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. Cellular Signalling, 2022, 96, 110358.	3.6	1
4	DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. Scientific Reports, 2021, 11, 11676.	3.3	4
5	Exploring the pathways to chronic lymphocytic leukemia. Blood, 2021, 138, 827-835.	1.4	20
6	Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies. Blood, 2021, 138, 1089-1089.	1.4	0
7	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood, 2021, 138, 1570-1582.	1.4	9
8	Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. Cellular and Molecular Life Sciences, 2021, 78, 6337-6349.	5.4	14
9	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 2020, 34, 640-644.	7.2	12
10	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. Clinical Cancer Research, 2020, 26, 1700-1711.	7.0	13
11	Celebrating 20 Years of IGHV Mutation Analysis in CLL. HemaSphere, 2020, 4, e334.	2.7	16
12	IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. Blood, 2020, 135, 834-844.	1.4	23
13	Introduction to a review series on understanding and treating primary immunodeficiency. Blood, 2020, 135, 591-591.	1.4	0
14	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clinical Cancer Research, 2019, 25, 2503-2512.	7.0	23
15	Introduction to a review series on biological insights into lymphoid tumors. Blood, 2018, 131, 2275-2275.	1.4	0
16	Critical influences on the pathogenesis of follicular lymphoma. Blood, 2018, 131, 2297-2306.	1.4	48
17	Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. Cancer Immunology, Immunotherapy, 2018, 67, 627-638.	4.2	28
18	Introduction to a review series on therapeutic antibodies. Blood, 2018, 131, 1-1.	1.4	47

#	Article	IF	Citations
19	Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 2017, 3, 16096.	30.5	363
20	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2313-2324.	7.0	51
21	B-Cell Tumors. , 2017, , 441-446.		0
22	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clinical Cancer Research, 2016, 22, 4827-4836.	7.0	24
23	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood, 2016, 128, 816-826.	1.4	54
24	Introduction to a review series on advances in cell-based immune therapeutics in hematology. Blood, 2016, 127, 3293-3293.	1.4	2
25	Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. Current Topics in Microbiology and Immunology, 2016, 405, 123-143.	1.1	6
26	IL-4 enhances expression and function of surface IgM in CLL cells. Blood, 2016, 127, 3015-3025.	1.4	76
27	Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood, 2016, 127, 449-457.	1.4	56
28	A plant-expressed conjugate vaccine breaks CD4⁺ tolerance and induces potent immunity against metastatic Her2⁺ breast cancer. OncoImmunology, 2016, 5, e1166323.	4.6	36
29	PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2Î± phosphorylation in established cell lines and primary human leukemia cells. Oncotarget, 2016, 7, 74807-74819.	1.8	7
30	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood, 2015, 126, 1902-1910.	1.4	79
31	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the EÂµ-TCL1 mouse model. Blood, 2015, 125, 4032-4041.	1.4	34
32	Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia. Haematologica, 2015, 100, e265-e268.	3.5	9
33	Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLoS ONE, 2015, 10, e0118096.	2.5	58
34	Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T Cells. PLoS ONE, 2015, 10, e0136717.	2.5	23
35	Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood, 2015, 125, 3287-3296.	1.4	66
36	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunology, Immunotherapy, 2015, 64, 1021-1032.	4.2	27

#	Article	IF	Citations
37	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica, 2014, 99, 1138-1148.	3.5	87
38	The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. Seminars in Hematology, 2014, 51, 158-167.	3.4	42
39	Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood, 2014, 124, 3101-3109.	1.4	34
40	B-cell Tumors. , 2014, , 1-6.		0
41	Genetic Vaccines against Cancer. , 2013, , 223-239.		1
42	DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. International Journal of Cancer, 2013, 133, 1400-1407.	5.1	13
43	Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood, 2013, 122, 2664-2672.	1.4	58
44	Targeting B-cell anergy in chronic lymphocytic leukemia. Blood, 2013, 121, 3879-3888.	1.4	73
45	An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunity, 2013, 13, 16.	3.2	10
46	Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood, 2012, 119, 3659-3667.	1.4	31
47	Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood, 2012, 119, 1726-1736.	1.4	52
48	Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood, 2012, 119, 170-179.	1.4	85
49	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. Blood, 2012, 119, 2106-2109.	1.4	11
50	DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunology, Immunotherapy, 2012, 61, 2161-2170.	4.2	89
51	B-cell receptor signaling in chronic lymphocytic leukemia. Blood, 2011, 118, 4313-4320.	1.4	331
52	High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen. Blood, 2011, 118, 650-659.	1.4	6
53	DNA fusion vaccines enter the clinic. Cancer Immunology, Immunotherapy, 2011, 60, 1147-1151.	4.2	21
54	DNA fusion gene vaccines induce cytotoxic Tâ€cell attack on naturally processed peptides of human prostateâ€specific membrane antigen. European Journal of Immunology, 2011, 41, 2447-2456.	2.9	15

#	Article	IF	Citations
55	B-Cell Tumors. , 2011, , 351-356.		0
56	The normal IGHV1-69â€“derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood, 2010, 115, 71-77.	1.4	83
57	Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood, 2010, 115, 4198-4205.	1.4	54
58	Understanding and activating immunity against human cancer. Current Opinion in Immunology, 2010, 22, 212-214.	5.5	5
59	The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Seminars in Cancer Biology, 2010, 20, 391-399.	9.6	42
60	Bystander stimulation of activated CD4⁺ T cells of unrelated specificity following a booster vaccination with tetanus toxoid. European Journal of Immunology, 2010, 40, 976-985.	2.9	51
61	DNA vaccines against cancer come of age. Current Opinion in Immunology, 2010, 22, 264-270.	5.5	63
62	Harnessing Innate Immunity to Suppress Lymphoma. Journal of Clinical Oncology, 2010, 28, 4295-4296.	1.6	4
63	Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18587-18592.	7.1	151
64	Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. International Immunology, 2010, 22, 875-887.	4.0	38
65	DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Human Gene Therapy, 2009, 20, 1269-1278.	2.7	172
66	Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin. Vaccine, 2009, 27, 4289-4296.	3.8	7
67	Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood, 2009, 113, 4677-4680.	1.4	56
68	Surface IgM of Chronic Lymphocytic Leukemia Cells Displays Unusual Glycans Indicative of Antigen Engagement In Vivo.. Blood, 2009, 114, 55-55.	1.4	0
69	Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide â€“ MHC classâ€„I complexes. European Journal of Immunology, 2008, 38, 364-369.	2.9	32
70	DNA fusion gene vaccination mobilizes effective antiâ€leukemic cytotoxic Tâ€„lymphocytes from a tolerized repertoire. European Journal of Immunology, 2008, 38, 2118-2130.	2.9	20
71	DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer, 2008, 8, 108-120.	28.4	388
72	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Molecular Immunology, 2008, 45, 1567-1572.	2.2	52

#	Article	IF	Citations
73	A DNA Fusion Vaccine Induces Bactericidal Antibodies to a Peptide Epitope from the PorA Porin of Neisseria meningitidis. Infection and Immunity, 2008, 76, 334-338.	2.2	16
74	DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood, 2008, 112, 2956-2964.	1.4	61
75	Prolonged Antigen Expression following DNA Vaccination Impairs Effector CD8+ T Cell Function and Memory Development. Journal of Immunology, 2007, 179, 8313-8321.	0.8	22
76	Human Follicular Lymphoma Cells Contain Oligomannose Glycans in the Antigen-binding Site of the B-cell Receptor. Journal of Biological Chemistry, 2007, 282, 7405-7415.	3.4	117
77	Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood, 2007, 109, 4424-4431.	1.4	212
78	Cancer Vaccines. , 2007, , 183-204.		4
79	Lineage complexity in multiple myeloma?. Leukemia and Lymphoma, 2006, 47, 1997-1998.	1.3	2
80	Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood, 2006, 107, 2806-2813.	1.4	65
81	PASD1 is a potential multiple myelomaâ€“associated antigen. Blood, 2006, 108, 3953-3955.	1.4	21
82	Optimizing cancer immunotherapy trials: Back to basics. European Journal of Immunology, 2006, 36, 1070-1073.	2.9	5
83	Structural and Functional Features of the B-Cell Receptor in IgG-Positive Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2006, 12, 1672-1679.	7.0	40
84	DNA Fusion Vaccines Induce Epitope-Specific Cytotoxic CD8+ T Cells against Human Leukemia-Associated Minor Histocompatibility Antigens. Cancer Research, 2006, 66, 5436-5442.	0.9	21
85	Prime-Boost with Alternating DNA Vaccines Designed to Engage Different Antigen Presentation Pathways Generates High Frequencies of Peptide-Specific CD8+ T Cells. Journal of Immunology, 2006, 177, 6626-6633.	0.8	31
86	Immunoglobulin Heavy Chain Locus Events and Expression of Activation-Induced Cytidine Deaminase in Epithelial Breast Cancer Cell Lines. Cancer Research, 2006, 66, 3996-4000.	0.9	119
87	Failure of Vaccination With Idiotypic Protein or DNA, (+/???IL-2), the Depletion of Regulatory T Cells, or the Blockade of CTLA-4 to Prolong Dormancy in Mice With BCL1 Lymphoma. Journal of Immunotherapy, 2005, 28, 525-534.	2.4	6
88	Update on cancer vaccines. Current Opinion in Oncology, 2005, 17, 573-577.	2.4	22
89	Deregulated expression of the Myc cellular oncogene drives development of mouse â€œBurkitt-likeâ€• lymphomas from naive B cells. Blood, 2005, 105, 2135-2137.	1.4	38
90	Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology, 2005, 114, 441-449.	4.4	139

#	Article	IF	Citations
91	Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax. Genetic Vaccines and Therapy, 2005, 3, 3.	1.5	8
92	Idiotype Gene Rescue in Follicular Lymphoma. , 2005, 115, 145-172.		1
93	Identification and Assembly of V Genes as Idiotype-Specific DNA Fusion Vaccines in Multiple Myeloma. , 2005, 113, 105-120.		4
94	Electroporation as a â€œPrime/Boostâ€•Strategy for Naked DNA Vaccination against a Tumor Antigen. Journal of Immunology, 2005, 174, 6292-6298.	0.8	100
95	Determining Mutational Status of Immunoglobulin V Genes in Chronic Lymphocytic Leukemia: A Useful Prognostic Indicator. , 2005, 115, 129-144.		5
96	Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10987-10992.	7.1	24
97	VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine, 2005, 23, 1931-1940.	3.8	23
98	Turning genes into cancer vaccines. Discovery Medicine, 2005, 5, 37-42.	0.5	0
99	DNA Fusion Vaccines Induce Targeted Epitope-Specific CTLs against Minor Histocompatibility Antigens from a Normal or Tolerized Repertoire. Journal of Immunology, 2004, 173, 4492-4499.	0.8	28
100	DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14646-14652.	7.1	109
101	Tumor Vaccines. Advances in Immunology, 2004, 82, 49-103.	2.2	22
102	Common Patterns of B Cell Perturbation and Expanded V4-34 Immunoglobulin Gene Usage in Autoimmunity and Infection. Autoimmunity, 2004, 37, 9-15.	2.6	36
103	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. British Journal of Haematology, 2004, 124, 604-609.	2.5	7
104	DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunological Reviews, 2004, 199, 156-180.	6.0	78
105	DNA vaccines and adjuvants. Immunological Reviews, 2004, 199, 5-8.	6.0	30
106	Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood, 2004, 103, 4389-4395.	1.4	347
107	Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events. Blood, 2004, 103, 2795-2798.	1.4	35
108	Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood, 2004, 104, 3312-3317.	1.4	84

#	Article	IF	Citations
109	B Cells Producing Pathogenic Autoantibodies. , 2004, , 381-401.		5
110	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 136-141.	2.2	37
111	Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. British Journal of Haematology, 2003, 120, 217-222.	2.5	56
112	Anti-idiotype vaccines. British Journal of Haematology, 2003, 123, 770-781.	2.5	27
113	PML-RARAâ€“targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nature Medicine, 2003, 9, 1413-1417.	30.7	72
114	Vaccine Therapy in NHL: Future Promises and Current Limitations. Leukemia and Lymphoma, 2003, 44, S85-S90.	1.3	2
115	Engineering DNA Vaccines that Include Plant Virus Coat Proteins. Biotechnology and Genetic Engineering Reviews, 2003, 20, 101-116.	6.2	9
116	Proteomic Analysis of Chronic Lymphocytic Leukemia Subtypes with Mutated or Unmutated Ig VH Genes. Molecular and Cellular Proteomics, 2003, 2, 1331-1341.	3.8	32
117	Immunotherapy of Hematologic Malignancy. Hematology American Society of Hematology Education Program, 2003, 2003, 331-349.	2.5	67
118	Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood, 2003, 101, 1087-1093.	1.4	279
119	Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood, 2003, 101, 3082-3084.	1.4	64
120	Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. Blood, 2003, 101, 4137-4139.	1.4	25
121	Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma. Blood, 2003, 102, 1872-1876.	1.4	8
122	Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen. Journal of Immunology, 2002, 169, 3908-3913.	0.8	79
123	Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen. Journal of Immunology, 2002, 169, 3777-3782.	0.8	96
124	CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood, 2002, 99, 1023-1029.	1.4	555
125	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 2002, 99, 2562-2568.	1.4	237
126	V H gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood, 2002, 100, 2659-2661.	1.4	39

#	Article	IF	Citations
127	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood, 2002, 100, 1505-1507.	1.4	105
128	A ?-herpesvirus immune evasion gene allows tumor cellsin vivo to escape attack by cytotoxic T cells specific for a tumor epitope. European Journal of Immunology, 2002, 32, 3481-3487.	2.9	22
129	Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Immunology, 2002, 107, 39-45.	4.4	20
130	DNA gene fusion vaccines against cancer. Current Opinion in Molecular Therapeutics, 2002, 4, 41-8.	2.8	9
131	Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer Research, 2002, 62, 1757-60.	0.9	27
132	Immunogenetic analysis reveals that epitope shifting occurs during B-cell affinity maturation in primary biliary cirrhosis11Edited by J. Karn. Journal of Molecular Biology, 2001, 306, 37-46.	4.2	15
133	DNA fusion vaccines against B-cell tumors. Trends in Molecular Medicine, 2001, 7, 566-572.	6.7	26
134	Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood, 2001, 98, 1174-1181.	1.4	77
135	The occurrence and significance of V gene mutations in B cellâ€"Derived human malignancy. Advances in Cancer Research, 2001, 83, 81-116.	5.0	95
136	Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: The molecule versus the mimic. Hepatology, 2001, 33, 792-801.	7.3	54
137	Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nature Biotechnology, 2001, 19, 760-764.	17.5	71
138	DNA Fusion Vaccine Designed to Induce Cytotoxic T Cell Responses Against Defined Peptide Motifs: Implications for Cancer Vaccines. Journal of Immunology, 2001, 167, 1558-1565.	0.8	90
139	DNA Fusion Vaccines Against B-Cell Tumors. , 2000, 29, 405-424.		0
140	Immunogenetic analysis of the immune response to pneumococcal polysaccharide. European Journal of Immunology, 2000, 30, 1214-1223.	2.9	70
141	IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. British Journal of Haematology, 2000, 109, 71-80.	2.5	16
142	Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia. Blood, 2000, 95, 3534-3540.	1.4	42
143	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood, 2000, 96, 2550-2556.	1.4	12
144	Immunogenetic analysis of the immune response to pneumococcal polysaccharide. , 2000, 30, 1214.		1

#	Article	IF	Citations
145	Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia. Blood, 2000, 95, 3534-3540.	1.4	3
146	A human monoclonal antibody encoded by the V4-34 gene segment recognises melanoma-associated ganglioside via CDR3 and FWR1. Human Antibodies, 1999, 9, 95-106.	1.5	11
147	Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia. Blood, 1999, 94, 1848-1854.	1.4	2,376
148	VH Gene Analysis of IgM-Secreting Myeloma Indicates an Origin From a Memory Cell Undergoing Isotype Switch Events. Blood, 1999, 94, 1070-1076.	1.4	46
149	VH Gene Sequences From Primary Central Nervous System Lymphomas Indicate Derivation From Highly Mutated Germinal Center B Cells With Ongoing Mutational Activity. Blood, 1999, 94, 1738-1746.	1.4	145
150	VH gene sequences from a novel tropical splenic lymphoma reveal a naive B cell as the cell of origin. British Journal of Haematology, 1999, 107, 114-120.	2.5	11
151	Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine, 1999, 17, 3030-3038.	3.8	53
152	VH Gene Sequences From Primary Central Nervous System Lymphomas Indicate Derivation From Highly Mutated Germinal Center B Cells With Ongoing Mutational Activity. Blood, 1999, 94, 1738-1746.	1.4	4
153	Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia. Blood, 1999, 94, 1848-1854.	1.4	78
154	DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Medicine, 1998, 4, 1281-1286.	30.7	283
155	Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunological Reviews, 1998, 162, 247-259.	6.0	132
156	Clonally related IgE and IgG4 transcripts in blood lymphocytes of patients with asthma reveal differing patterns of somatic mutation. European Journal of Immunology, 1998, 28, 3354-3361.	2.9	29
157	VH gene analysis of Burkitt's lymphoma in children from north-western Iran. British Journal of Haematology, 1998, 103, 1116-1123.	2.5	7
158	Immunogenetic analysis of a panel of monoclonal IgG and IgM anti-PDC-E2/X antibodies derived from patients with primary biliary cirrhosis. Journal of Hepatology, 1998, 28, 582-594.	3.7	15
159	Immunogenetic analysis of the heavy chain variable regions of IgE from patients allergic toÂpeanutsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 101, 391-396.	2.9	33
160	VH Gene Analysis of Clonally Related IgM and IgG From Human Lymphoplasmacytoid B-Cell Tumors With Chronic Lymphocytic Leukemia Features and High Serum Monoclonal IgG. Blood, 1998, 91, 238-243.	1.4	38
161	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. Blood, 1998, 91, 4292-4299.	1.4	133
162	A Pilot Study of Idiotypic Vaccination for Follicular B-cell Lymphoma Using a Genetic Approach. University of Bristol, Bristol, United Kingdom. Human Gene Therapy, 1997, 8, 1287-1299.	2.7	29

#	Article	IF	Citations
163	Phage surface expression for analysis of recognition sites of human autoantibodies: Comparison of single chain Fv and Fab. Human Antibodies, 1997, 8, 124-128.	1.5	2
164	Myeloma VL and VH Gene Sequences Reveal a Complementary Imprint of Antigen Selection in Tumor Cells. Blood, 1997, 89, 219-226.	1.4	90
165	Differential Rates of Somatic Hypermutation in VH Genes Among Subsets of Chronic Lymphocytic Leukemia Defined by Chromosomal Abnormalities. Blood, 1997, 89, 4153-4160.	1.4	208
166	Use of Phage Expression to Analyze Regions of a Human V4-34(VH4-21)-encoded IgG Autoantibody Required for Recognition of DNA No Involvement of the 9G4 Idiotope. Annals of the New York Academy of Sciences, 1997, 815, 338-341.	3.8	0
167	Pattern of usage and somatic hypermutation in the VH5 gene segments of a patient with asthma: Implications for IgE. European Journal of Immunology, 1997, 27, 162-170.	2.9	44
168	The I Binding Specificity of Human VH4-34 (VH4-21) Encoded Antibodies is Determined by Both VHFramework Region 1 and Complementarity Determining Region 3. Journal of Molecular Biology, 1996, 256, 577-589.	4.2	94
169	Immunogenetics of human IgE. Human Antibodies, 1996, 7, 157-166.	1.5	10
170	Idiotypic vaccination against low grade follicular B cell lymphoma. , 1996, , 299-304.		0
171	The Immunoglobulin V_H Gene, V_H4â€“21, Specifically Encodes Autoantiâ€Red Cell Antibodies against the I or i Antigens. Vox Sanguinis, 1995, 68, 231-235.	1.5	31
172	Idiotypic DNA Vaccines Against B-cell Lymphoma. Immunological Reviews, 1995, 145, 211-228.	6.0	118
173	The Immunoglobulin V(H) Gene, V(H)4-21, Specifically Encodes Autoanti-Red Cell Antibodies against the I or i Antigens. Vox Sanguinis, 1995, 68, 231-235.	1.5	21
174	Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: A possible link between infection and lupus. Human Antibodies, 1995, 6, 52-56.	1.5	38
175	Hodgkin's Disease â€" New Insights from Immunoglobulin Genetics. New England Journal of Medicine, 1995, 333, 934-936.	27.0	3
176	Pattern of usage of the VH4â€“21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. Molecular Immunology, 1995, 32, 347-353.	2.2	20
177	A Genetic Approach to Idiotypic Vaccination for B Cell Lymphoma. Annals of the New York Academy of Sciences, 1995, 772, 212-226.	3.8	25
178	Dual Recognition of Lipid A and DNA by Human Antibodies Encoded by the V_H4â€21 Gene A Possible Link between Infection and Lupus^a. Annals of the New York Academy of Sciences, 1995, 764, 427-432.	3.8	13
179	Biased utilization of immunoglobulin variable region heavy- and light-chain genes by the malignant CD5- B lymphocytes from patients with Burkitt's lymphoma. International Journal of Cancer, 1994, 58, 226-232.	5.1	11
180	Antiâ€i: Human Cold Agglutinins Recognizing Linear (i) and Branched (I) Type 2 Chains. Vox Sanguinis, 1994, 67, 216-221.	1.5	11

#	Article	IF	Citations
181	Differential usage of an autoantibody-associated VH gene by human B-cell tumors. , 1994, , 163-172.		0
182	Utilization of the VH4-21 Gene Segment by Anti-DNA Antibodies from Patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 1993, 6, 809-825.	6.5	107
183	A Genetic Approach to Idiotypic Vaccination. Journal of Immunotherapy, 1993, 14, 273-278.	2.4	58
184	Update on tumor vaccines. International Journal of Clinical and Laboratory Research, 1992, 22, 84-89.	1.0	8
185	Characterisation of a light chain loss variant of the BCL1 lymphoma. Molecular Immunology, 1991, 28, 789-799.	2.2	4
186	Tumor vaccines. FASEB Journal, 1991, 5, 2250-2257.	0.5	17
187	Monoclonal Antibodies Raised Against the Idiotype of the Murine B Cell Lymphoma, BCL₁Act Primarily with Heavy Chain Determinants. Hybridoma, 1991, 10, 219-227.	0.6	21
188	Humoral effector mechanisms in the immunity to cancer. Trends in Immunology, 1990, 11, 348-349.	7.5	2
189	Anti-Idiotypic Therapy of Leukemias and Lymphomas (Part 1 of 2). Chemical Immunology and Allergy, 1989, 48, 126-146.	1.7	18
190	Prospects for the Treatment of B Cell Tumors Using Idiotypic Vaccination. International Reviews of Immunology, 1989, 4, 271-310.	3.3	56
191	Heterogeneity in neoplastic cell populations in chronic lymphocytic leukaemia defined by immunoglobulin expression and secretion in vitro. Leukemia Research, 1988, 12, 123-127.	0.8	1